

Medicine: entrectinib (brand name: Rozlytrek®)

Roche Products Ltd

The Scottish Medicines Consortium (SMC) has assessed entrectinib for the treatment of advanced non-small cell lung cancer (NSCLC) that is ROS1-positive. Entrectinib was assessed for use on its own in adults who have not previously been treated with medicines that work in a similar way. This document summarises the SMC decision and what it means for patients.

What has SMC said?

After careful consideration, SMC has accepted entrectinib for treating adults with ROS1-positive NSCLC as described above.

This SMC advice takes into account a confidential discount offered by the pharmaceutical company that improves the cost-effectiveness of entrectinib. In addition SMC was able to apply a more flexible approach* in the assessment, as it is for a rare condition.

What does SMC's decision mean for patients?

If your healthcare professional thinks that entrectinib for use as described above is the right medicine for you, you should be able to have the treatment on the NHS in Scotland



What is entrectinib used for?

Entrectinib is used to treat a type of lung cancer called non-small cell lung cancer (NSCLC). It is for those patients whose cancer cells have a genetic change (mutation) that affects the gene responsible for making a protein called ROS1. This occurs in around 1-2% of patients with NSCLC. The mutation leads to a faulty version of the ROS1 protein being produced. Entrectinib is used on its own in patients with advanced NSCLC and the ROS1 gene mutation (known as ROS1 positive NSCLC) who have not already been treated with a ROS1 inhibitor.

How does entrectinib work?

Cancer cells with a mutation in the ROS1 gene produce a faulty ROS1 protein that causes uncontrolled growth of the cells. Entrectinib blocks the actions of the faulty ROS1 protein which can help to slow down the growth of the cancer.

*<https://www.scottishmedicines.org.uk/how-we-decide/pace/>

How does SMC make its decision?

SMC carefully considers every new medicine to make sure it benefits patients and is considered to be an acceptable use of the limited resources in NHSScotland.

To do this SMC considers the following:

- Evidence from the company about how well the medicine works compared with current treatments available in Scotland, in relation to how much they will cost to buy and administer.
- Information from patient groups about the potential impact of the medicine on patients and carers.
- Advice from healthcare professionals about any benefits of the new medicine compared to current treatment, along with how the new medicine is likely to be used.

When SMC assesses a medicine it takes account of the needs of all patients in NHSScotland, not just those who may be treated with the medicine under consideration.

You can find more detailed information about the SMC assessment of entrectinib by looking at the SMC Detailed Advice Document (SMC2294).

More information

The organisations below can provide more information and support for people with lung cancer and their families. SMC is not responsible for the content of any information provided by external organisations.

Roy Castle Lung Cancer Foundation



<https://www.roycastle.org>



0333 323 7200

Scottish Lung Cancer Nurses Forum – affiliated to Lung Cancer Nursing UK



<http://www.lcnuk.org>



01675 477607

You can find out more about entrectinib (Rozlytrek®) in the European public assessment report (EPAR) summary for the public by searching for the medicine name on the European Medicines Agency (EMA) website.



<http://www.ema.europa.eu>